Physician profile
James Stackhouse
NPI 1750517710
$16,792.75
in general payments reported to CMS, 2019-2025
24 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,061 · 2020: $349 · 2021: $320 · 2022: $904 · 2023: $716 · 2024: $1,204 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,433 · Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,432.50 |
| Food and Beverage | $2,726.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $9,890.18 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $2,343.48 | 2019-2022 | |
| Alcon Vision LLC | $1,814.54 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Glaukos Corporation | $743.10 | 2020-2025 | Idose, Idosetr |
| Abbvie INC. | $740.57 | 2022-2025 | Durysta |
| Kala Pharmaceuticals, INC. | $234.18 | 2019-2021 | |
| New World Medical,INC. | $152.26 | 2019-2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Allergan, INC. | $124.57 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $120.51 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $109.19 | 2020 | |
| Ocular Therapeutix, INC. | $90.19 | 2023-2024 | Dextenza |
| Sight Sciences, INC. | $89.33 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $72.65 | 2022-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.62 | 2021 | |
| Harrow Eye, LLC | $44.46 | 2024 | Iheezo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $38.19 | 2025 | Envista Envy Iol |
| Sun Pharmaceutical Industries INC. | $26.79 | 2022 | |
| Optos, INC. | $25.40 | 2019 | |
| Dompe US, INC. | $17.48 | 2021 | |
| Oyster Point Pharma, INC. | $17.00 | 2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $15.54 | 2024 | Acthar |
| Coopervision INC. | $13.78 | 2019 | |
| Biotissue Holdings INC. | $12.66 | 2021 | |
| Medtronic Vascular, INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stackhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.